Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines
about
Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerNKT cell networks in the regulation of tumor immunityTGF-β signaling and its targeting for glioma treatmentThe neuroprotective functions of transforming growth factor beta proteinsImmunocompetent murine models for the study of glioblastoma immunotherapyAntibody-based immunotherapy for malignant glioma.Overview of cellular immunotherapy for patients with glioblastoma.Strategies to use immune modulators in therapeutic vaccines against cancerAugmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production.Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.Overexpressed oncogenic tumor-self antigensCharacterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessmentImmunosuppressive mechanisms in glioblastoma.Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophagesImmune-checkpoint blockade and active immunotherapy for glioma.The polarization of immune cells in the tumour environment by TGFbeta.Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model.Improving cancer immunotherapy by targeting tumor-induced immune suppression.Targeting Tregs in Malignant Brain Cancer: Overcoming IDO.Transforming growth factor-beta and its implication in the malignancy of gliomas.Microenvironmental clues for glioma immunotherapy.T-cell epitope finding on EPHA2 for further glioma vaccine development: An immunomics study.Transforming growth factor β and bone morphogenetic protein actions in brain tumors.The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy.Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta.Developing immunotherapeutic strategies to target brain tumors.Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression.
P2860
Q26749451-E787C576-9F3C-4D13-97ED-AE5C274294F7Q26866223-C0D76CD4-B6B0-48F5-AFED-F7587A04EF96Q28082042-7E5DA735-D0CF-4296-B811-963F8893B56DQ28274093-AD50D0D2-684C-45D6-B954-AA737CF55E62Q33574853-2E1D61CA-16B9-4500-B435-F8EC2ED09BEDQ34120472-751EDA0D-AED3-4F74-AE00-C95FB6492C14Q34189694-D861BCE4-7FD9-442E-BD17-781439B481C6Q34275601-B6F1452D-C0B0-4185-ADE6-3E84B50F7B95Q34744217-E7C2E051-251E-4122-8632-C78DDB51E885Q34744555-BE3933D7-80C2-41D9-92AA-B267E5E4D5C9Q35117549-A3F7054B-1848-457B-BC68-97D188C6CEB7Q35145392-A977263D-7473-4D97-975E-241AB49CE2D0Q35561280-C6DA8BE2-7D41-460F-8F6B-3D5FE03ABA07Q35886756-C9DECD36-F050-4D72-8A46-F0DF9ECC403FQ35964158-7EF45474-EBAC-4B7D-9CB2-11188CA85435Q36224048-E7217BF5-2899-4610-88AD-24D10744FF56Q36484434-92E0F411-6A41-4F33-8026-62F4A2920033Q36710130-16D4D198-7377-42FC-B651-49FB3E3E0FADQ37092938-0DC6974F-4776-4484-9861-8C547E7EF9D7Q37420586-443295AF-9E90-44BC-BB90-520AE610263EQ37454364-4DAE4AF3-488C-449B-9AEF-EDA05F869A72Q37730613-84D979AB-2910-42F8-A1E9-76F21AA0097AQ37814208-8DB16FD4-18A0-4D2E-B75C-89C651A920C6Q37830362-1B1591C9-AD14-47B9-97DE-A8AFC197205FQ38110540-2FE7EFF8-DD2C-49A4-8557-55E3C3CE73F2Q38192972-FFE2FFA9-1921-47CF-B49D-65DB0897D219Q38194054-258B5FFB-CE60-4373-A721-2D9972E7154CQ38445885-47F778D4-AFB8-44D9-A6F4-2756737D2794Q38469127-3B9AFE3D-9EC4-4B24-8022-E7A58D750C89Q38617733-9522747F-BB2A-404E-8444-EDE92326EB64Q38675900-EF80C7F5-03FD-4319-80B0-900A33139058Q38714700-0B84FDCA-7B55-4C1A-8D38-54AC36D51C0DQ38737954-468DA95D-8D55-4660-A59C-3F262AAEB4CEQ38789860-33048DB3-C334-40A0-AE6D-19D57A01DAFEQ38843924-FEFEE95F-7319-401B-A9BB-09B852E67B4EQ38851464-4579B528-FE4D-48BF-83C5-4B5A628DA66AQ39036703-64CCDFEA-864D-4F7D-800B-5B18EF398E0BQ39196377-88C50092-9324-4115-BF7B-C3C9D3A6D08BQ41870476-8DC25155-F338-4B87-988C-9C47E9D6A6D3Q41892306-8A6895D4-8A72-4DA2-B998-1DB606F5A4D5
P2860
Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic inhibition of transfo ...... iated antigen peptide vaccines
@en
Systemic inhibition of transfo ...... ated antigen peptide vaccines.
@nl
type
label
Systemic inhibition of transfo ...... iated antigen peptide vaccines
@en
Systemic inhibition of transfo ...... ated antigen peptide vaccines.
@nl
prefLabel
Systemic inhibition of transfo ...... iated antigen peptide vaccines
@en
Systemic inhibition of transfo ...... ated antigen peptide vaccines.
@nl
P2093
P2860
P1476
Systemic inhibition of transfo ...... iated antigen peptide vaccines
@en
P2093
Edward R Kastenhuber
Heather A McDonald
Hideho Okada
Jay Harper
Kotaro Sasaki
Scott Lonning
Xinmei Zhu
P2860
P304
P356
10.1158/1078-0432.CCR-09-1067
P407
P577
2009-10-27T00:00:00Z